EMA CVMP Regulatory Deep-Dive: Key Products & Scientific Opinions Under Review

AMSTERDAM, NETHERLANDS — The European Medicines Agency’s (EMA) Committee for Veterinary Medicinal Products (CVMP) concluded its plenary session spanning September 8 to September 10, 2026. The formal CVMP Meeting Highlights document will be published shortly on the EMA portal.

Core Products & Topics Evaluated

1. Regenerative Medicine (Canine Adipose-Derived Mesenchymal Stem Cells):

   • Scope: Evaluation of an initial marketing authorization application (Procedure ID: EMEA/V/C/006457/0000) for a novel stem-cell therapy targeting osteoarthritis and severe degenerative joint disease in dogs.

   • Regulatory Significance: Represents a continued push by the CVMP to establish clear bioequivalence, quality control, and safety frameworks for veterinary Novel Therapies (Novel Animal Health Products).

2. Post-Authorisation Variations (Prevomax® – Maropitant):

   • Scope: Review of a major variation procedure (EMA/VRA/0000337350) for Dechra’s injectable antiemetic Prevomax®.

   • Focus: Updates concerning quality specifications, shelf-life extensions, and safety profile alignments across EU member states.

3. Maximum Residue Limits (MRLs) & Environmental Risk Assessments (ERA):

   • Review of scientific data establishing MRLs for active pharmaceutical ingredients used in food-producing species (cattle, swine, and aquaculture) to ensure consumer safety and food supply protection across the EU single market.

4. Pharmacovigilance & Union Pharmacovigilance Database:

   • Signal management updates derived from the Union Pharmacovigilance Database, standardizing continuous safety monitoring for biologicals and antiparasitics across all EU member states.